• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

8.030 -0.110 (-1.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Polyrizon Ltd. - Ordinary Shares

< Previous 1 2 Next >
News headline image
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Today 7:20 EST
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
December 19, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
December 11, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
December 08, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential
December 04, 2025
Via AB Newswire
Topics Artificial Intelligence Death
News headline image
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
December 04, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
December 03, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
December 02, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
November 06, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
October 06, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
September 19, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
September 12, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Regains Compliance with Nasdaq Listing Requirements
August 14, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Peraso (NASDAQ: PRSO) The Future of mmWave Technology as Takeover Bid Underscores Surging Confidence – More Stocks Inside
July 22, 2025
Via AB Newswire
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
July 22, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Retains Nasdaq Listing Following Hearings Panel
July 15, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
June 12, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Receipt of Nasdaq Delisting Notice
May 23, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
May 21, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
May 13, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
April 25, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
April 11, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $17M in Private Placement
April 02, 2025
Via Investor Brand Network
News headline image
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
April 02, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
April 01, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Ltd. Announces $17.0 Million Private Placement
March 31, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
March 27, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
March 25, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
March 19, 2025
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
March 14, 2025
From Polyrizon Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap